Related references
Note: Only part of the references are listed.Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies
Zhong-Yi Dong et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy
Pieter-Jan van Dam et al.
SEMINARS IN CANCER BIOLOGY (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Diagnostic significance of intratumoral CD8+tumor-infiltrating lymphocytes in medullary carcinoma
Fumie Igari et al.
HUMAN PATHOLOGY (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz et al.
LABORATORY INVESTIGATION (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Seung Tae Kim et al.
JOURNAL OF CANCER (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
Edward C. Stack et al.
METHODS (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients
Jan Franko et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors A Finding Derived From Analysis of Islet Cell Differentiation Markers
Lizhi Zhang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
Thorvardur R. Halfdanarson et al.
ENDOCRINE-RELATED CANCER (2008)
Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors
V Deshpande et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms
A Rahman et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Share Paper
